ORIC · CIK 0001796280
What ORIC Pharmaceuticals, Inc. told the SEC could break it.
ORIC's disclosures cluster on a single dependency: it sources the active pharmaceutical ingredients for its drug candidates from third-party suppliers, including manufacturers in China, which pulls in a stack of U.S.-China policy exposures — roughly 30% tariffs on Chinese-origin goods, heightened FDA scrutiny of China-based facilities, and a DOJ rule limiting data transfers to China-linked partners. Underneath that supply-chain risk sits the fragility of a clinical-stage company with no product revenue, a $129.5 million net loss in 2025, and a reliance on continued access to capital markets. It also flags that its candidates may need companion diagnostic tests it would depend on others to develop.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- China tariffs (30%+), FDA China-contractor scrutiny, and DOJ China data-transfer rulehigh
ORIC faces U.S.-China policy risk on its China-linked supply/contracting — ~30% tariffs (plus a 10% reciprocal baseline) on Chinese-origin goods with a pharmaceutical-tariff investigation ongoing, heightened FDA scrutiny of China-based drug facilities, and a DOJ rule limiting transfers of sensitive personal data to China-linked partners.
“since February 4, 2025, the U.S. government has imposed additional tariffs on the import of almost all Chinese origin goods which are now 30% and an additional baseline reciprocal 10% tariff on certain products of most other U.S. tra”
SEC filing →As of 2026
Liquidity & debt
- $129.5M 2025 net loss; $692.2M accumulated deficit; no product revenuemedium
ORIC has never generated product revenue, posted a $129.5M net loss in 2025 (accumulated deficit $692.2M) and expects continued losses for years; it funds operations via equity offerings/private placements, leaving it dependent on capital-market access.
“Our net loss was $129.5 million for the year ended December 31, 2025, and as of December 31, 2025, we had an accumulated deficit of $692.2 million.”
SEC filing →As of 2026
Other disclosures
- dependence on third parties to develop required companion diagnostic testsmedium
ORIC is exploring predictive biomarkers and may need companion diagnostic tests for patient selection; inability to develop these, significant delays, or reliance on third parties could prevent it from realizing the full commercial potential of its product candidates.
“If we are unable to successfully develop any required companion diagnostic tests for our product candidates, experience significant delays in doing so, or rely on third parties in the development of such companion diagnostic tests, we may not realize the full commercial potential of our product candidates.”
SEC filing →As of 2026
Supplier concentration
- dependence on third-party suppliers, including China-based API manufacturersmedium
ORIC depends on third-party suppliers — including certain China-based manufacturers that provide the active pharmaceutical ingredients (API) for its product candidates — and expects to keep relying on global suppliers; loss or supply failure of these parties would harm its development.
“We depend on third-party suppliers, including from certain manufacturers located in China that provide us with active pharmaceutical ingredients (API) required for the production of our product candidates, and we expect to continue to depend on third-party suppliers located in various jurisdictions around the world.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Mirati Therapeutics, Inc.
“under the Mirati License Agreement was an upfront payment of 588,235 shares of our common stock, issued pursuant to a stock issuance agreement entered into between the parties on August 3, 2020.”
Cited →Voronoi Inc.
“Under the Voronoi License Agreement, Voronoi was responsible for certai”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch